Stevenage, United Kingdom

Savvas Kleanthous


Average Co-Inventor Count = 4.8

ph-index = 1

Forward Citations = 5(Granted Patents)


Location History:

  • London, GB (2002)
  • Stevenage, GB (2007 - 2008)

Company Filing History:


Years Active: 2002-2008

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Savvas Kleanthous: Innovator in Vascular Disease Treatment

Introduction: Savvas Kleanthous is a distinguished inventor based in Stevenage, GB, who has made significant contributions to the field of pharmaceutical innovation. With six patents to his name, Kleanthous has demonstrated a profound commitment to advancing medical treatments, particularly in relation to acute vascular diseases.

Latest Patents: Among his latest inventions are noteworthy compounds that act as inhibitors for factor Xa, a critical enzyme linked to blood coagulation. His patent titled "1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases" focuses on novel compounds of formula (I), wherein the substituents are defined meticulously for their pharmacological effect. Another significant patent is for "3-sulfonylamino-pyrrolidine-2-one derivatives as inhibitors of factor Xa," which also delves into compounds of formula (I) aimed at mitigating vascular-related health issues.

Career Highlights: Kleanthous has built a solid reputation through his work in prominent pharmaceutical companies. He has had enriching experiences at SmithKline Beecham Corporation and Glaxo Group Limited, where he contributed to various research and development projects that led to innovative drug solutions. His expertise and creative engineering have propelled his career forward, culminating in multiple patent registrations that speak to his innovative spirit.

Collaborations: Throughout his career, Savvas Kleanthous has collaborated with esteemed colleagues such as Robert John Young and Paul John Beswick. These partnerships have enabled him to synergize innovative ideas and enhance the quality of his inventions, ultimately leading to breakthroughs in therapeutic agents for vascular diseases.

Conclusion: Savvas Kleanthous exemplifies the essence of innovation within the pharmaceutical sector. His patents not only represent advancements in medical treatment but also highlight his dedication to improving patient outcomes. As he continues to explore new horizons in research and development, the impact of his work will undoubtedly resonate within the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…